Tempest Therapeutics Inc (NASDAQ:TPST) does about 2.81M shares in volume on a normal day but saw 4529451 shares change hands in the recent trading day. The company now has a market cap of 36.30M USD. Its current market price is $1.44, marking a decrease of -7.10% compared to the previous close of $1.55. The 52 week high reached by this stock is $9.77 whilst the lowest price level in 52 weeks is $0.17.
Tempest Therapeutics Inc (TPST) has a 20-day trading average at $1.5311 and the current price is -85.26% off the 52-week high compared with 747.06% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.0462 and its 200-day simple moving average is $3.3029. If we look at the stock’s price movements over the week, volatility stands at 35.87%, which decreases to 15.33% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 43.36 to suggest the stock is neutral.
The consensus objective for the share price is $19.50, suggesting that the stock has a potential upside of 92.62% over the period.
1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 14, 2024 when Scotiabank initiated the stock to “Sector Outperform” and issued a price target of $13.
Tempest Therapeutics Inc (TPST) stock is up 25.22% over the week and -26.15% over the past month. Its price is -67.27% year-to-date and 123.60% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.35 and -1.52 for whole year.
To reach the target analysts have set, the stock logically needs to grow 92.62 percent from here.
Outstanding shares total 22.05M with insiders holding 0.24% of the shares and institutional holders owning 22.43% of the company’s common stock. The company has a return on investment of -114.99% and return on equity of -289.26%. The beta has a value of -1.80. Price to book ratio is 2.08.
